Found: 2
Select item for more details and to access through your institution.
Oxaliplatin-Free Interval as a Risk Factor for Hypersensitivity Reaction among Colorectal Cancer Patients Treated with FOLFOX.
- Published in:
- Oncology, 2010, v. 79, n. 1/2, p. 136, doi. 10.1159/000320613
- By:
- Publication type:
- Article
Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).
- Published in:
- 2011
- By:
- Publication type:
- journal article